Deborah J. Moonan, RN, BSN, Director, Continuing Education, has disclosed that she has no relevant financial relationships.
Ann Gianola, MA, Manager, Continuing Education Accreditation & Program Operations, has disclosed that she has no relevant financial relationships.
Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, has disclosed that she has no relevant financial relationships.
Rashmi Kumar, PhD, Senior Manager, Clinical Content, has disclosed that she has no relevant financial relationships.
Maria Ho, PhD, Oncology Scientist/Senior Medical Writer, has disclosed that she has no relevant financial relationships.
Kiel MJ, Velusamy T, Betz BL et al.. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med 2012;209:1553–1565.
Samowitz WS, Sweeney C, Herrick J et al.. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063–6069.
Marchetti A, Felicioni L, Malatesta S et al.. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011;29:3574–3579.
Paik PK, Arcila ME, Fara M et al.. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011;29:2046–2051.
Grisham RN, Iyer G, Garg K et al.. Braf mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 2013;119:548–554.
Chapman PB, Hauschild A, Robert C et al.. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507–2516.
Greaves WO, Verma S, Patel KP et al.. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn 2013;15:220–226.
Su F, Viros A, Milagre C et al.. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207–215.
Pakneshan S, Salajegheh A, Smith R, Lam A. Clinicopathological relevance of BRAF mutations in human cancer. Pathol 2013;45:346–356.
Balch CM, Soong SJ, Smith T et al.. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001;8:101–108.
Xi L, Arons E, Navarro W et al.. Both variant and ighv4-34–expressing hairy cell leukemia lack the BRAF V600E mutation. Blood 2012;119:3330–3332.
Chung SS, Kim E, Park JH et al.. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med 2014;6:238ra71.
Champion KJ, Bunag C, Estep AL et al.. Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome. Clin Genet 2011;79:468–474.